Rationale and evidence to combine radiation therapy and immunotherapy for cancer treatment

[1]  Rainer Fietkau,et al.  Radio-Immunotherapy-Induced Immunogenic Cancer Cells as Basis for Induction of Systemic Anti-Tumor Immune Responses – Pre-Clinical Evidence and Ongoing Clinical Applications , 2015, Front. Immunol..

[2]  A. Ribas.  Adaptive Immune Resistance: How Cancer Protects from Immune Attack. , 2015, Cancer discovery.

[3]  S. Demaria,et al.  Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial. , 2015, The Lancet. Oncology.

[4]  J. Zavadil,et al.  TGFβ Is a Master Regulator of Radiation Therapy-Induced Antitumor Immunity. , 2015, Cancer research.

[5]  Joe Y. Chang,et al.  The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant. , 2015, Cancer treatment reviews.

[6]  H. Kohrt,et al.  Ablative Tumor Radiation Can Change the Tumor Immune Cell Microenvironment to Induce Durable Complete Remissions , 2015, Clinical Cancer Research.

[7]  Sean S. Park,et al.  PD-1 Restrains Radiotherapy-Induced Abscopal Effect , 2015, Cancer Immunology Research.

[8]  H. Ishwaran,et al.  Radiation and Dual Checkpoint Blockade Activates Non-Redundant Immune Mechanisms in Cancer , 2015, Nature.

[9]  P. Lambin,et al.  Radiotherapy Combined with the Immunocytokine L19-IL2 Provides Long-lasting Antitumor Effects , 2014, Clinical Cancer Research.

[10]  P. Hegde,et al.  MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer , 2014, Nature.

[11]  R. Weichselbaum,et al.  STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors. , 2014, Immunity.

[12]  R. Fietkau,et al.  Norm- and hypo-fractionated radiotherapy is capable of activating human dendritic cells , 2014, Journal of immunotoxicology.

[13]  I. Stratford,et al.  Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. , 2014, Cancer research.

[14]  D. Gomez,et al.  Combining Radiation and Immunotherapy: A New Systemic Therapy for Solid Tumors? , 2014, Cancer Immunology Research.

[15]  Mansoor M Ahmed,et al.  Unlocking the Combination: Potentiation of Radiation-Induced Antitumor Responses with Immunotherapy , 2014, Radiation research.

[16]  N. Agarwal,et al.  Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. , 2014, The Lancet. Oncology.

[17]  P. Ascierto,et al.  Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy , 2014, Oncoimmunology.

[18]  R. Weichselbaum,et al.  Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. , 2014, The Journal of clinical investigation.

[19]  A. Bhatia,et al.  Cellular and molecular mechanisms in cancer immune escape: a comprehensive review , 2014, Expert review of clinical immunology.

[20]  D. Getnet,et al.  Combined treatment effects of radiation and immunotherapy: studies in an autochthonous prostate cancer model. , 2013, International journal of radiation oncology, biology, physics.

[21]  A. Kumari,et al.  Turning T cells on: epigenetically enhanced expression of effector T-cell costimulatory molecules on irradiated human tumor cells , 2013, Journal of Immunotherapy for Cancer.

[22]  John Wong,et al.  Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. , 2013, International journal of radiation oncology, biology, physics.

[23]  M. Sznol,et al.  Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer , 2013, Clinical Cancer Research.

[24]  K. Iwamoto,et al.  Maximizing tumor immunity with fractionated radiation. , 2012, International journal of radiation oncology, biology, physics.

[25]  R. Johnstone,et al.  Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies. , 2012, Cancer research.

[26]  W. Urba,et al.  Phase 1 Study of Stereotactic Body Radiotherapy and Interleukin-2—Tumor and Immunological Responses , 2012, Science Translational Medicine.

[27]  Dong Yu,et al.  An In Situ Autologous Tumor Vaccination with Combined Radiation Therapy and TLR9 Agonist Therapy , 2012, PloS one.

[28]  R. Hannan,et al.  Combined immunotherapy with Listeria monocytogenes-based PSA vaccine and radiation therapy leads to a therapeutic response in a murine model of prostate cancer , 2012, Cancer Immunology, Immunotherapy.

[29]  Jedd D. Wolchok,et al.  Immunologic correlates of the abscopal effect in a patient with melanoma. , 2012, The New England journal of medicine.

[30]  J. Hodge,et al.  Abscopal regression of antigen disparate tumors by antigen cascade after systemic tumor vaccination in combination with local tumor radiation. , 2012, Cancer biotherapy & radiopharmaceuticals.

[31]  H. Nagawa,et al.  Intratumoral injection of interleukin‐2 augments the local and abscopal effects of radiotherapy in murine rectal cancer , 2011, Cancer science.

[32]  Axel Hoos,et al.  Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. , 2011, The New England journal of medicine.

[33]  L. Tenenbaum,et al.  Development of a successful antitumor therapeutic model combining in vivo dendritic cell vaccination with tumor irradiation and intratumoral GM-CSF delivery , 2011, Cancer Immunology, Immunotherapy.

[34]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[35]  H. Shirato,et al.  Local radiation therapy inhibits tumor growth through the generation of tumor-specific CTL: its potentiation by combination with Th1 cell therapy. , 2010, Cancer research.

[36]  Xuefang Cao.  Regulatory T cells and immune tolerance to tumors , 2010, Immunologic research.

[37]  N. Kawashima,et al.  Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti–CTLA-4 Antibody , 2009, Clinical Cancer Research.

[38]  R. Weichselbaum,et al.  Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. , 2009, Blood.

[39]  H. Shirato,et al.  Combination immunotherapy with radiation and CpG‐based tumor vaccination for the eradication of radio‐ and immuno‐resistant lung carcinoma cells , 2009, Cancer science.

[40]  S. Steinberg,et al.  High‐dose interleukin‐2 for the treatment of metastatic renal cell carcinoma , 2008, Cancer.

[41]  K. Camphausen,et al.  The Use of Chelated Radionuclide (Samarium-153-Ethylenediaminetetramethylenephosphonate) to Modulate Phenotype of Tumor Cells and Enhance T Cell–Mediated Killing , 2008, Clinical Cancer Research.

[42]  S. Gerber,et al.  Radiation-Induced IFN-γ Production within the Tumor Microenvironment Influences Antitumor Immunity1 , 2008, The Journal of Immunology.

[43]  K. Camphausen,et al.  Use of radiolabeled monoclonal antibody to enhance vaccine-mediated antitumor effects , 2008, Cancer Immunology and Immunotherapy.

[44]  M. Nishimura,et al.  Combination tumor immunotherapy with radiotherapy and Th1 cell therapy against murine lung carcinoma , 2007, Clinical & Experimental Metastasis.

[45]  James B. Mitchell,et al.  Gene expression profiling of breast, prostate, and glioma cells following single versus fractionated doses of radiation. , 2007, Cancer research.

[46]  B. Nelson,et al.  Standard Treatments Induce Antigen-Specific Immune Responses in Prostate Cancer , 2007, Clinical Cancer Research.

[47]  W. Mendenhall,et al.  Adjuvant radiotherapy for cutaneous melanoma: comparing hypofractionation to conventional fractionation. , 2006, International journal of radiation oncology, biology, physics.

[48]  T. Waldmann.  The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design , 2006, Nature Reviews Immunology.

[49]  K. Camphausen,et al.  Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy , 2006, The Journal of experimental medicine.

[50]  S. Rosenberg,et al.  IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. , 2006, Blood.

[51]  I. Lax,et al.  Regression of non-irradiated metastases after extracranial stereotactic radiotherapy in metastatic renal cell carcinoma , 2006, Acta oncologica.

[52]  M. Gordon.  Randomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2 and Interferon in Patients With Metastatic Renal Cell Carcinoma , 2006 .

[53]  Robert C. Rose,et al.  Local Radiation Therapy of B16 Melanoma Tumors Increases the Generation of Tumor Antigen-Specific Effector Cells That Traffic to the Tumor1 , 2005, The Journal of Immunology.

[54]  N. Kawashima,et al.  Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[55]  L. Milas,et al.  Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances tumor response to fractionated radiotherapy. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[56]  C. N. Coleman,et al.  External Beam Radiation of Tumors Alters Phenotype of Tumor Cells to Render Them Susceptible to Vaccine-Mediated T-Cell Killing , 2004, Cancer Research.

[57]  Sun-Hee Kim,et al.  Direct injection of immature dendritic cells into irradiated tumor induces efficient antitumor immunity , 2004, International journal of cancer.

[58]  N. Kawashima,et al.  Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. , 2004, International journal of radiation oncology, biology, physics.

[59]  Fumito Ito,et al.  Radiotherapy potentiates the therapeutic efficacy of intratumoral dendritic cell administration. , 2003, Cancer research.

[60]  S. Steinberg,et al.  Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  K. Camphausen,et al.  Radiation abscopal antitumor effect is mediated through p53. , 2003, Cancer research.

[62]  Luca Scorrano,et al.  A novel mitochondriotoxic small molecule that selectively inhibits tumor cell growth. , 2002, Cancer cell.

[63]  C. Chiang,et al.  Combining radiation therapy with interleukin-3 gene immunotherapy , 2000, Cancer Gene Therapy.

[64]  B. Vikram,et al.  Flt3-ligand administration after radiation therapy prolongs survival in a murine model of metastatic lung cancer. , 1999, Cancer research.

[65]  K. Konoeda.  [Therapeutic efficacy of pre-operative radiotherapy on breast carcinoma: in special reference to its abscopal effect on metastatic lymph-nodes]. , 1990, Nihon Gan Chiryo Gakkai shi.

[66]  R. Rees,et al.  Interleukin-2 and cancer therapy. , 1990, Cancer cells.

[67]  J. Le Bourgeois,et al.  [Whole body irradiation]. , 1989, Pathologie-biologie.

[68]  Mole Rh.  Whole body irradiation; radiobiology or medicine? , 1953 .